Le Lézard
Classified in: Health, Science and technology
Subject: Stock Split

CORRECTING and REPLACING Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023


First paragraph, first sentence of release should read: Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt or the "Company"), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced today that it will effect a 1-for-40 reverse split of its common stock (instead of Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt or the "Company"), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced today that it will effect a 1-for-40 reverse split of its common stock effective as of 9:30 a.m. Eastern Time on August 18, 2023).

The updated release reads:

ADITXT, INC. (NASDAQ: ADTX) ANNOUNCES 1-FOR-40 REVERSE STOCK SPLIT EFFECTIVE AT THE OPEN OF TRADING ON AUGUST 18, 2023

Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt or the "Company"), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced today that it will effect a 1-for-40 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on August 18, 2023, the Company's common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company's stockholders at the annual meeting held on August 16, 2023, with the final ratio determined by the Company's board of directors.

As a result of the reverse stock split, the CUSIP number for the Company's common stock will now be 007025604. As a result of the reverse stock split, every 40 shares of issued and outstanding common stock will be exchanged for 1 share of common stock, with any fractional shares being rounded up to the next higher whole share. Immediately after the reverse stock split becomes effective, the Company will have approximately 190,319 shares of common stock issued and outstanding.

The reverse stock split is primarily intended to bring the Company into compliance with Nasdaq's minimum bid price requirement.

Additional information concerning the reverse stock split can be found in Aditxt's definitive proxy statement filed with the Securities and Exchange Commission on July 20, 2023, as amended.

About Aditxt, Inc.

Aditxt®, Inc. (NASDAQ: ADTX) is a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system. Headquartered in Richmond, Virginia, with operations in Silicon Valley, California, and New York, New York. Aditxt's mission "Making Promising Innovations Possible, Together" is defined by our growing ecosystem of research institutions, global industry partners and shareholders who inform and inspire our mission. Aditxt's diverse innovation portfolio includes: Adimunetm, Inc., aimed at developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivirtm, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases; and Pearsantatm, Inc., which intends to offer personalized immune monitoring for a wide range of health conditions, including hereditary cancer, wounds and cardiomyopathy.

For more information, visit the Company's websites at www.Aditxt.com, www.Adimune.com and www.Pearsanta.com. Follow us on LinkedIn for the latest company news.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product and business development; the Company's ability to finance and execute on its strategic M&A initiatives; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.


These press releases may also interest you

at 03:04
Experts Live Europe, a premier conference for IT professionals and technology enthusiasts, is thrilled to announce Samantha Alleyne as the keynote speaker for its upcoming event in Budapest. Taking place on September 23-25, 2024, the conference...

3 mai 2024
In the news release, Nomic Unveils Bitcoin Liquid Staking Token Powered by Babylon's Bitcoin Staking Protocol, issued 10-Apr-2024 by Nomic DAO Foundation over PR Newswire, we are advised by the company that the dateline should read "GEORGE TOWN,...

3 mai 2024
United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, will unveil its latest MRI technology, boasting incredible advancements across various fronts, as a Gold sponsor at this year's ISMRM meeting. The...

3 mai 2024
Affiliated Dermatologists (AD) is providing notice of a recent data security incident. At this time, AD is not aware of any misuse of any personal information in connection with this incident. What Happened? On March 5, 2024, AD detected it was the...

3 mai 2024
BetterLife Pharma Inc. ("BetterLife" or the "Company") , an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, today announced that the Company intends to...

3 mai 2024
Celonis, the global leader in Process Mining, today announced it has appointed Mark Jacobs to the role of Senior Vice President North America Sales. As the Go-to-Market leader for North America, Jacobs will work closely with new and existing...



News published on and distributed by: